Ann Lab Med.  2018 Sep;38(5):492-494. 10.3343/alm.2018.38.5.492.

PCM1-JAK2 Fusion in a Patient With Acute Myeloid Leukemia

• Lee JM
• Lee J
• Han E
• Kim M
• Kim Y
• Han K
• Kim HJ

• KMID: 2434743
• DOI: http://doi.org/10.3343/alm.2018.38.5.492

Abstract

No abstract available.

MeSH Terms

Humans
Leukemia, Myeloid, Acute*

Figure

• 

  Fig. 1 Bone marrow (BM) findings. (A) Myeloblasts showing less cytoplasm and distinct prominent nucleoli at initial diagnosis (April 2011) (Wright stain, ×400); (B) CD34-positive myeloblasts in the BM biopsy (November 2011) (immunohistochemistry stain, ×400); (C) increased immature cells in touch preparation (March 2012) (Wright stain, ×400); (D–F) serial BM biopsies showing fibrosis progression (April 2011, November 2011, and March 2012, respectively) (hematoxylin & eosin stain ×200).

• 

  Fig. 2 The t(8;9)(p21;p24) translocations and PCM1-JAK2 fusion gene. (A) Karyogram of BM showing 46,XX,t(8;9)(p21;p24), (B) Sequence of the chimeric PCM1-JAK2 gene showing in-frame fusion between exon 30 of PCM1 and exon 9 of JAK2.

Reference

1. Bain BJ. Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities? Br J Haematol. 2014; 166:809–817. PMID: 24913195.

2. Song I, Lee DH, Lee JH, Jang S, Huh JR, Seo EJ. A t(8;9)(p22;p24)/PCM1-JAK2 translocation in a patient with myeloproliferative neoplasm and myeloid sarcoma: first report in Korea. Ann Lab Med. 2016; 36:79–81. PMID: 26522767.

3. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391–2405. PMID: 27069254.

4. Schwaab J, Knut M, Haferlach C, Metzgeroth G, Horny HP, Chase A, et al. Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes. Ann Hematol. 2015; 94:233–238. PMID: 25260694.

5. Patterer V, Schnittger S, Kern W, Haferlach T, Haferlach C. Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1. Ann Hematol. 2013; 92:759–769. PMID: 23400675.

6. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005; 65:2662–2667. PMID: 15805263.

7. Arber DA, Brunning RD, Orazi A. Acute myeloid leukaemia, not otherwise specified. In : Swerdlow SH, Campo E, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer (IARC);2008. p. 134–135.

8. Rumi E, Milosevic JD, Casetti I, Dambruoso I, Pietra D, Boveri E, et al. Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. J Clin Oncol. 2013; 31:e269–e271. PMID: 23630205.

9. Lierman E, Selleslag D, Smits S, Billiet J, Vandenberghe P. Ruxolitinib inhibits transforming JAK2 fusion proteins in vitro and induces complete cytogenetic remission in t (8; 9)(p22; p24)/PCM1-JAK2–positive chronic eosinophilic leukemia. Blood. 2012; 120:1529–1531. PMID: 22899477.

10. Reiter A. Myeloid neoplasms with eosinophilia. Blood. 2017; 129:704–714. PMID: 28028030.